Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo

Circulation

Volumn 99, Issue 23, 1999, Pages 3043-3049

  Fabre, Jean Etienne ^a   Rivard, Alain ^a   Magner, Meredith ^a   Silver, Marcy ^a   Isner, Jeffrey M ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Angiotensin; Growth substances; Ischemia

Indexed keywords

ACETYLCHOLINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; NITROPRUSSIDE SODIUM; QUINAPRIL; QUINAPRILAT; RECOMBINANT VASCULOTROPIN; SEROTONIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CAPILLARY DENSITY; COLLATERAL CIRCULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; INTRAARTERIAL DRUG ADMINISTRATION; LEG ANGIOGRAPHY; LIMB ISCHEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE SPECIFICITY; VASCULAR RESISTANCE; VASOMOTOR REFLEX;

EID: 0033564447     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.23.3043     Document Type: Article

References (41)

1. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;23:258-268.
2. Caldwell PR, Seegal BC, Hsu KC. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976;191:1050-1051.
3. Van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Speriti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90:362-368.
4. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
5. Dzau VJ. Molecular and physiological aspects of tissue renin-angiotensin systems: emphasis on cardiovascular control. J Hypertens. 1988;6: 7S-12S.
6. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard A, Pepine C, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study. Circulation. 1996;94: 258-265.
7. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996; 27:760-765.
8. Le Noble FA, Schreurs NH, van Straaten HW, Slaaf DW, Smits JF, Rogg H, Struijker-Boudier HA. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol. 1993;264:R460-R465.
9. Volpert OV, Ward WF, Lingen MW, Chester L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98: 671-679.
10. Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension. 1990;15: 68-77.
11. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia. 1992;35:12-18.
12. Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneural angiogenesis in streptozotocin-diabetic rats. Diabetologia. 1993;36:1230-1237.
13. Olivetti G, Cigola E, Lagrasta C. Ricci R, Quaini F, Monopoli A, Ongini E. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;21:362-370.
14. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989;7:267-275.
15. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 1997;29: 478-482.
16. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest. 1994;93:662-670.
17. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Physiologic assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol. 1994;267: H1263-H1271.
18. Ziada AM, Hudlicka O, Tyler KR, Wright AJ. The effect of long-term vasodilation on capillary growth and performance in rabbit heart and skeletal muscle. Cardiovasc Res. 1984;18:724-732.
19. Fabris B, Chen B, Pupic V, Perich R. Inhibition of tissue angiotensin-converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol. 1990;15:6-13.
20. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation. 1993;87:283-290.
21. Prins EJ, Hoorntje SJ, Weening JJ, Donker AJ. Nephrotoxic syndrome in patients with captopril. Lancet. 1979;2:306-307.
22. Gavras I, Graff LG, Rome BD, McKenna JM, Brunner HR, Gavras H. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981;94:58-59.
23. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 1995;25:913-917.
24. Chua CC, Hamdy RC, Chua BHL. Upregulation of vascular endothelial growth factor by Ang II in rat heart ECs. Biochim Biophys Acta. 1998; 1401:187-194.
25. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
26. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
27. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
28. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997;95:1030-1037.
29. Ziehe M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
30. Ziehe M, Parenti A, Ledda F, Dell'Era P, Granger HJ, Maggi CA, Presta M. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res. 1997;80:845-852.
31. Zhang X, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen. Circulation. 1997;95:176-182.
32. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
33. Warren JB, Loi RK. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J. 1995;9:411-418.
34. Van Belle E, Vallet B, Auffray JL, Bauters C, Hamon M, Lablanche JM, Dupuis B, Bertrand ME. NO synthesis is involved in the structural and functional effects of ACE inhibitors, in injured arteries. Am J Physiol. 1996;270:H298-H305.
35. Dimmeler S, Rippman V, Weiland U, Haendeler J, Zeiher AM. Ang II induces apoptosis of human ECs: protective effect of nitric oxide. Circ Res. 1997;81:970-976.
36. Morbidelli L, Parenti A, Giovanelli L, Granger HJ, Ledda F, Ziehe M. B1 receptor involvement in the effect of bradykinin on venular EC proliferation and potentiation of FGF-2 effects. Br J Pharmacol. 1998;124: 1288-1292.
37. Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Scholkens BA, Wiemer G, Unger T. Long term low dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension. 1993;22:682-687.
38. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman B, Griendling K, Harrison D. Ang II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97: 1916-1923.
39. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;929(suppl II):II-365-II-371.
40. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endotheliai growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97: 381-390.
41. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240.